Eli Lilly &reason 01 of 4it owns a thing that cannot be built or permitted twicederived 2026-09-11accession 0000059478-26-000081
Tirzepatide (Mounjaro/Zepbound) has created a franchise approaching two-thirds of total revenue with volume growth exceeding 40% in both U.S. and international markets. Manufacturing capacity investments should convert constrained supply into additional volume, extending the growth runway before competitive incretins mature.
the thesis · admitted · the reason above is the thesis, not printed twice
no findingread · nothing bore on it
It held on this filing. No finding was written because nothing in it bore on the reason — the sentences it was read against are below.
the evidence · every sentence checkedsix sentences · whole, uncut
the claims it rests on
“Mounjaro and Zepbound accounted for 65 percent of our total revenue for the six months ended June 30, 2026”
“Revenue of Mounjaro increased 45 percent and 51 percent in the U.S. during the three and six months ended June 30, 2026, respectively”
“Revenue of Zepbound increased 44 percent and 58 percent in the U.S. during the three and six months ended June 30, 2026, respectively”
“Revenue outside the U.S. during the three and six months ended June 30, 2026 was $5.2 billion and $9.6 billion, respectively, compared to $1.9 billion and $3.1 billion during the three and six months ended June 30, 2025, respectively, primarily driven by volume growth”
“To support anticipated demand for our current and prospective products, we have undertaken significant manufacturing expansion initiatives. Additional capacity is expected to become operational over the next several years”
what it was checked against
volume growth driven by tirzepatide
“Revenue increased for the three and six months ended June 30, 2026, driven primarily by increased volume, partially offset by lower realized prices. The increased volume and the lower realized prices during the three and six months ended June 30, 2026 were primarily driven by Mounjaro and Zepbound.”